EGFR and non-small cell lung carcinoma: Several previous studies in NSCLC indicate that Tp53 is frequently co-mutation with EGFR mutation, which is involved in survival rate of patients treated with 1st and 2nd generation tyrosine kinase inhibitors (TKI) [20].